Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
This selectivity is important because it suggests the compound affects only its intended target rather than causing widespread metabolic disruption
Methylcobalamin, on the other hand, skips that conversion and directly enters B12-dependent biochemical reactions
Other peptides like CJC-1295 or AOD-9604 are marketed for fat loss, but unlike GLP-1 drugs, they lack robust human data and are not FDA-approved for obesity (FDA warning on unapproved peptides)
NNMT (Nicotinamide N-Methyltransferase) Inhibition Potently and selectively binds to the nicotinamide binding site of NNMT, blocking the methylation of nicotinamide using SAM 4
Because the mechanism targets cytokine signaling cascades that amplify through second-messenger systems
Current Research and Future Trends Expanding Clinical Applications Ongoing studies are exploring the role of AOD-9604 in treating metabolic conditions such as: Type 2 diabetes Insulin resistance Non-alcoholic fatty liver disease (NAFLD) Up to 95% of individuals with type 2 diabetes also present with NAFLD, emphasizing the need for multi-functional metabolic therapies Joint Health & Cartilage Regeneration In addition to fat metabolism, AOD-9604 may stimulate cartilage repair and support joint health
